BIOMAT Database Logo BIOMAT Database Logo

[Phase I study of orally administered UFT plus l-leucovorin]. 1998

N Horikoshi, and K Aiba, and R Kanamaru, and K Hasegawa, and S Takeda, and T Taguchi, and H Niitani, and H Furue, and M Kurihara, and M Ogawa, and T Abe
Cancer Chemotherapy Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research.

A Phase I study of UFT plus l-LV was conducted in 29 patients (pts) with G.I. cancer on a multicenter cooperative study. UFT and l-LV were given orally in two divided doses for 28 consecutive days, followed by a 14 day-rest period. UFT was fixed in three doses, 250, 313 and 375 mg/m2/day, and l-LV was increased in dose from 25 to 50 and to 100 mg/body/days. Dose-limiting toxicities were anorexia, diarrhea, and nausea/vomiting. The maximum tolerated dose of UFT was 375 mg/m2/day, and l-LV 25 mg/body/day. Severe myelotoxicity was not observed. There were three responders (PR) out of 21 pts with measurable disease at UFT doses of 313 mg/m2/day and l-LV 50 and 100 mg/body/day. Responses observed were abdominal mass (rectal ca), liver metastasis (pancreas ca) and metastasis of liver and lymph-node (gastric ca). As a result of pharmacokinetics, plasma concentrations of 5-methyl-THF were maintained > 1.0 microM for over 5 hours that was considered to have a modulating effect on the plasma concentration. In doses of 50 mg and 100 mg/body/day of l-LV. No accumulations in plasma were observed in patient treated in 28 days by l-LV/UFT therapy. It was suggested UFT and l-LV did not interfere with each other's absorption. A Phase II study is recommended, with doses of 313 mg/m2/day of UFT and 50 or 100 mg/body/day of l-LV.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D005770 Gastrointestinal Neoplasms Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL. Gastrointestinal Cancer,Cancer of Gastrointestinal Tract,Cancer of the Gastrointestinal Tract,Neoplasms, Gastrointestinal,Cancer, Gastrointestinal,Cancers, Gastrointestinal,Gastrointestinal Cancers,Gastrointestinal Neoplasm,Gastrointestinal Tract Cancer,Gastrointestinal Tract Cancers,Neoplasm, Gastrointestinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

N Horikoshi, and K Aiba, and R Kanamaru, and K Hasegawa, and S Takeda, and T Taguchi, and H Niitani, and H Furue, and M Kurihara, and M Ogawa, and T Abe
Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
September 1997, Oncology (Williston Park, N.Y.),
N Horikoshi, and K Aiba, and R Kanamaru, and K Hasegawa, and S Takeda, and T Taguchi, and H Niitani, and H Furue, and M Kurihara, and M Ogawa, and T Abe
[Combination chemotherapy with orally administered UFT and leucovorin (LV)].
August 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
N Horikoshi, and K Aiba, and R Kanamaru, and K Hasegawa, and S Takeda, and T Taguchi, and H Niitani, and H Furue, and M Kurihara, and M Ogawa, and T Abe
Rationale for phase I study of UFT plus leucovorin and oral JM-216.
September 1997, Oncology (Williston Park, N.Y.),
N Horikoshi, and K Aiba, and R Kanamaru, and K Hasegawa, and S Takeda, and T Taguchi, and H Niitani, and H Furue, and M Kurihara, and M Ogawa, and T Abe
Phase II study of UFT plus leucovorin in colorectal cancer.
January 1997, Oncology,
N Horikoshi, and K Aiba, and R Kanamaru, and K Hasegawa, and S Takeda, and T Taguchi, and H Niitani, and H Furue, and M Kurihara, and M Ogawa, and T Abe
A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.
July 2000, International journal of radiation oncology, biology, physics,
N Horikoshi, and K Aiba, and R Kanamaru, and K Hasegawa, and S Takeda, and T Taguchi, and H Niitani, and H Furue, and M Kurihara, and M Ogawa, and T Abe
A phase I study of paclitaxel, UFT, and leucovorin.
October 2000, Oncology (Williston Park, N.Y.),
N Horikoshi, and K Aiba, and R Kanamaru, and K Hasegawa, and S Takeda, and T Taguchi, and H Niitani, and H Furue, and M Kurihara, and M Ogawa, and T Abe
Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal.
January 1993, Anticancer research,
N Horikoshi, and K Aiba, and R Kanamaru, and K Hasegawa, and S Takeda, and T Taguchi, and H Niitani, and H Furue, and M Kurihara, and M Ogawa, and T Abe
Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
January 1998, Cancer investigation,
N Horikoshi, and K Aiba, and R Kanamaru, and K Hasegawa, and S Takeda, and T Taguchi, and H Niitani, and H Furue, and M Kurihara, and M Ogawa, and T Abe
Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.
January 1997, Investigational new drugs,
N Horikoshi, and K Aiba, and R Kanamaru, and K Hasegawa, and S Takeda, and T Taguchi, and H Niitani, and H Furue, and M Kurihara, and M Ogawa, and T Abe
High-dose radiotherapy and concurrent UFT plus l-leucovorin in locally advanced rectal cancer: a phase I trial.
January 2005, Acta oncologica (Stockholm, Sweden),
Copied contents to your clipboard!